Structural Heart Devices Market

Structural Heart Devices Market: By Product, Procedure, and Region

Market Synopsis

The global Structural Heart Devices Market is valued at USD 13.1 Billion in 2024 and is projected to reach a value of USD 35.65 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 9.55% between 2025 and 2035. Increase in prevalence of cardiovascular diseases and growing public and private investments for R&D activities are some of the factors that drive the demand for cardiac rhythm management devices such as implantable cardioverter defibrillators (ICDs), pacemakers, and ventricular assist devices. Also, large number of unmet needs such as increased incidence of coronary artery disease, heart failure & chronic kidney disease will result in high growth rates over the next five years. Moreover, technological advancements with respect to device design and procedure techniques further drives the growth rate. Devices will witness significant increase in usage across developing countries such as India, China, Brazil & Mexico owing to increasing prevalence of cardiovascular diseases. However, high cost associated with these devices may become a barrier in adoption of cardiac device technologies in some countries across the globe.

Growing Prevalence of Cardiovascular Diseases to Drive Demand for Structural Heart Devices

There has been a sharp increase in the prevalence of cardiovascular diseases and metabolic disorders in developing countries, and there is considerable evidence that these changes are occurring before the onset of aging. A number of environmental factors including diet, physical activity, socioeconomic circumstances and psychosocial stress have been cited as potential contributors to the increases in prevalence. However, their relative contributions have not been established. In the last several decades, it has been shown that cardiovascular diseases and metabolic disorders can be largely attributed to insulin resistance and hyperinsulinemia, which in turn lead to increased free fatty acid flux into non-adipose tissues and elevated non-esterified fatty acids (NEFA) concentrations in plasma.

Segmentation

On the basis of product, the market is segmented into heart valve devices, occluders and delivery systems, annuloplasty rings, and accessories. Based on procedure, the market is segmented into replacement and repair.

Heart Valve Devices (Transcatheter Mitral Valve) Implantation to Remain the Largest Contributor to the Structural Heart Devices Market

Introduction The global structural heart repair device market is segmented into transcatheter aortic valve implantation (TAVI), transcatheter mitral valve implantation (TMVI), and coronary artery bypass grafting (CABG) devices. Of these the TAVI devices are estimated to have the largest share of the overall market. TAVI devices are a less invasive procedure that has a lower risk of mortality as compared to cardiac surgery. Moreover, TAVI is primarily recommended for high-risk patients. Hence, the market growth of these devices is dependent on the number of surgeries performed in aging population with cardiac problems.

TAVI was primarily used in the developed countries in Europe and North America when it first came into practice in 2003. The European Society of Cardiology guidelines for treatment for severe aortic stenosis released in 2012 helped increase uptake rates significantly among this patient population particularly across Germany, Italy, UK, France, Belgium, and Switzerland. Furthermore, technological advancements over the past years have aided to improve procedural outcomes which consequently led to increased adoption rates. Advancements in TAVI devices have also led to a more widespread use of this technology, which was previously used on patients with high surgical risk.

Asia Pacific Structural Heart Devices Market to Witness Fastest Growth

Asia Pacific is likely to be the fastest growing region in the global market, with a CAGR of 11.2%. Key growth drivers include consistent positive outlook for cardiovascular care in Asia Pacific, growing geriatric population base coupled with high prevalence of cardiovascular diseases in emerging economies, and strong product pipeline offering compelling value proposition. Owing to large patient pool, favorable reimbursement scenario and advanced healthcare infrastructure, North America has been one of the largest markets for Structural Heart Devices. However increased penetration of minimally invasive surgery such as transcatheter aortic valve implantation (TAVI) & mitral valve repair/replacement surgery may lower utilization rates over the forecast period.

Vendor Landscape

Some of the key players in the global Structural Heart Devices market are Medtronic plc; Braile Biomedica, St. Jude Medical, Inc., Medical Technology Est., Micro Interventional Devices, Inc., Boston Scientific Corporation; LivaNova PLC, Edwards Lifesciences Corporation, Cryolife, Inc., and JenaValve Technology, Inc.

The Structural Heart Devices is Segmented as Follows: